Akums Drugs and Pharmaceuticals has introduced Paracetamol Oral Suspension 500mg/5ml in the Indian market, strengthening its position in pain and fever management and adding a significant product to the analgesic and antipyretic category.

This high-strength, easy-to-administer formulation is designed specifically for adult and geriatric patients, offering effective relief from pain and fever with a therapeutic dose in a minimal volume.

The company said the launch bridges the long-standing gap between paediatric syrups and conventional tablet formats, catering to patients who experience difficulty swallowing pills. 

According to Akums, the new oral suspension is among the most concentrated liquid paracetamol products available in India.

By delivering an effective adult dose in just 5ml, it significantly reduces dosing frequency and volume—particularly beneficial in outpatient, hospital, and home care settings across India.

It enables rapid symptom relief, especially in cases where IV access is unavailable or oral tablets are ineffective or cause discomfort.

The product is particularly suited for elderly patients, post-surgical recovery cases, and those with dysphagia or swallowing difficulties.

Compared to the commonly available 250mg/5ml suspensions that require 10–20ml per dose, Akums’ new formulation simplifies administration with a clear “5ml = 500mg” dosage. This is especially helpful in homecare and community health scenarios commonly seen in the Indian market.

Sandeep Jain, Joint Managing Director of Akums Drugs and Pharmaceuticals, said ‘’At Akums, we always strive to develop solutions that make a real difference in people’s lives. This new high-strength paracetamol suspension is a result of listening to what patients and caregivers truly need—something effective, easy to take, and less of a burden during times of illness.”

“Whether it’s for an elderly person struggling to swallow tablets or someone managing care at home, we believe this product will make treatment simpler and more comfortable. It’s another step in our journey to create accessible and thoughtful healthcare solutions for everyone,” he added.

While initially launched for the Indian market, Akums noted the formulation’s potential for international expansion, particularly in regions with similar healthcare dynamics and patient needs.

Akums is a leading contract development and manufacturing organization (CDMO), offering comprehensive pharmaceutical solutions—from R and D and regulatory support to large-scale commercial manufacturing.

With over 15 cutting-edge manufacturing facilities and more than 4,000 commercialised formulations, Akums partners with over 1,500 domestic and global clients, delivering across a broad spectrum of therapeutic categories.